Module 19. Case review - Non-Perfusion Imaging – Viability-Case review - Non-Perfusion Imaging

Video Transcription

Video Summary

In this video, Dr. Serge Harb, a cardiologist at the Cleveland Clinic, discusses the principles and applications of FDG PET imaging for assessing myocardial viability. He begins by explaining that FDG PET imaging relies on the uptake of fluorodeoxyglucose (FDG) which competes with glucose for transport and phosphorylation in the heart. He emphasizes that the goal of FDG PET imaging is to determine whether a reduction in myocardial blood flow at rest is due to scarred (non-viable) or hibernating (viable) myocardium. Scarred myocardium reflects dead tissue and is not worth revascularization, while hibernating myocardium should be revascularized as it may improve with treatment. Dr. Harb also discusses patient preparation for the test, which is critical to ensure optimal FDG uptake. He presents six case reviews to demonstrate the applications of FDG PET imaging in different clinical scenarios and explains how to interpret the images and make decisions regarding revascularization based on the presence of scar tissue, hibernating myocardium, or normal perfusion. The video concludes with a summary of the key teaching points and important considerations for using FDG PET imaging to assess myocardial viability.

Keywords

FDG PET imaging

myocardial viability

cardiologist

Cleveland Clinic

scarred myocardium

hibernating myocardium